NBC Securities’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.84K Hold
20
– – ﹤0.01% 2223
2026
Q2
$3.37K Sell
20
-3
-13% -$445 ﹤0.01% 2154
2026
Q1
$3.03K Hold
23
– – ﹤0.01% 2239
2025
Q4
$3.26K Sell
23
-1
-4% -$145 ﹤0.01% 2316
2025
Q3
$3.37K Buy
24
+2
+9% +$271 ﹤0.01% 2303
2025
Q2
$2K Buy
22
+2
+10% +$229 ﹤0.01% 2299
2025
Q1
$2K Buy
+20
New +$2.53K ﹤0.01% 2036
2024
Q4
– Sell
-20
Closed -$2K – 1784
2024
Q3
$2K Hold
20
– – ﹤0.01% 2031
2024
Q2
$2K Hold
20
– – ﹤0.01% 1993
2024
Q1
$2K Hold
20
– – ﹤0.01% 2001
2023
Q4
$2K Hold
20
– – ﹤0.01% 2021
2023
Q3
$2K Buy
+20
New +$2.11K ﹤0.01% 2016

Other funds holding NBIX

NBC Securities's NBIX Position: Q3 2026 in Review

NBC Securities held its Neurocrine Biosciences (NBIX) position steady in Q3 2026 at 20 shares worth $2.84K. The position accounts for ﹤0.01% of the portfolio, ranked #2223.

NBC Securities first reported a position in NBIX in Q3 2023 and has held it in 12 quarters since. The position peaked at $3.37K in Q2 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • NBC Securities held 20 shares of Neurocrine Biosciences worth $2.84K as of Q3 2026.
  • NBC Securities left its Neurocrine Biosciences share count unchanged in Q3 2026.
  • Neurocrine Biosciences made up ﹤0.01% of NBC Securities's portfolio in Q3 2026, its #2223 holding.
  • NBC Securities first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 12 quarters since.
  • NBC Securities's Neurocrine Biosciences position peaked at $3.37K in Q2 2026.
  • 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on NBC Securities's 13F filing for Q3 2026, filed 26 Oct 2026.